HAE · Haemonetics Corporation · Stock research

Current Thesis

The plasma re-acceleration re-rating that carried HAE from the May washout at $47.32 into the high-$70s has stalled. At $76.19 (July 10 close), the stock is roughly flat over two weeks and holding just under its 52-week high of $87.32, no longer extending. The narrative is intact and now widely held: IVIG-driven plasma collection lapping the lost CSL Plasma disposables pact, with fiscal 2027 the first clean-comp year. That ubiquity is the risk. Sell-side has finished flipping from spring cuts to summer raises, and Citi's July 8 move — target lifted to $79 from $70, still Neutral, paired with a "downside 90-day catalyst watch" — argues a beat-and-raise at the August 6 Q1 FY2027 print "may not be enough given the shift in expectations." The easy recovery off the low has been paid out; what remains is a binary earnings event into a stretched tape, with Interventional Technologies the unproven variable. This is a low-velocity defensive pivot re-rating on quarterly proof, and the next proof is a coin-flip four weeks out.

Bullish and bearish views on Haemonetics Corporation

The model's bull view on Haemonetics Corporation (HAE), in brief: Plasma re-acceleration is now the base-case story (Q4 FY2026, 2026-06-05): FY2026 Plasma was -2% reported but +20% organic ex-CSL ($524M revenue). The bear view: Citi's July 8 "downside 90-day catalyst watch" names the core risk: shares at YTD highs, and a likely beat-and-raise "may not be enough given the shift in expectations." The story has become consensus, and consensus into a print is thin reward for binary risk (2026-07-08). Both cases follow in full.

Bull Case

• Plasma re-acceleration is now the base-case story (Q4 FY2026, 2026-06-05): FY2026 Plasma was -2% reported but +20% organic ex-CSL ($524M revenue). FY2027 is the year reported growth reconnects to that underlying strength as the CSL drag fully annualizes.
• Sell-side finished flipping from cuts to raises: Mizuho $70→$85 Outperform on IVIG-driven plasma demand (2026-06-15); BTIG Buy $84 (2026-06-26); even Neutral-rated Citi lifted its target $70→$79 (2026-07-08). Consensus median sits ~$83–90 (range $74–108) with zero Sell ratings.
• FY2027 guide points to inflection (2026-06-05): +4–7% reported revenue, +3–6% organic, adjusted EPS broadly in line with revenue, ~80% FCF conversion, operating margin +50–100bps — a return to growth after two transition years.
• Float shrinking into the clean-comp year: completed a $300M buyback retiring ~8.68% of shares, a mechanical EPS tailwind. Hospital remains the engine — FY2026 revenue $588M, +4% organic, with TEG hemostasis leadership (2026-06-05).
• Even the cautious desk concedes the operations (2026-07-08): Citi's own note allows the company "may beat-and-raise" on August 6 — the trajectory is not in dispute, only whether it is priced.

Bear Case

• Citi's July 8 "downside 90-day catalyst watch" names the core risk: shares at YTD highs, and a likely beat-and-raise "may not be enough given the shift in expectations." The story has become consensus, and consensus into a print is thin reward for binary risk (2026-07-08).
• Interventional Technologies remains unproven (2026-06-05): Q4 FY2026 vascular closure -8%, MVP/MVP XL -6% in electrophysiology. Management's claim that ~80% of the decline is lapped or non-material is a forward assertion the August 6 print must validate.
• The move flattened rather than accelerated: $76.19 (July 10) sits below $77.62 (June 25), ~13% under the $87.32 high, with momentum cooling into the catalyst. A defensive medtech name that stops making higher highs before an earnings binary skews toward mean reversion.
• The re-rating already happened: +46% off the low with a ~37x P/E means most of the recovery multiple is in the price. There is little cushion if Q1 disappoints on IVT.
• The raises restore spring scars rather than open new ground: JPMorgan sits at Neutral $62, and Raymond James cut from Strong Buy to Outperform and pulled HAE from its Current Favorites over IVT execution (2026-05-28). The bull targets largely recover lost ground.

Setup & Price Structure

• Trading $76.19 (July 10 close, +1.6% on the day), market cap ~$3.46B, P/E ~37x. 52-week range $47.32–$87.32 — upper third, ~13% below the high and ~61% above the low.
• The reclaimed May–June breakout shelf near $70 is the structural line and the pivot Citi anchored its raised $79 target to; a failed print retests it.
• Two-week action is a stall just under YTD highs: the +46% recovery leg has gone sideways rather than pushing toward the high. No pullback to moving-average support, and no fresh breakout above $80 either.
• It re-rates on quarterly proof points, not weekly narrative velocity — a defensive legacy pivot, not a theme leader.

Catalyst Calendar (next 30 days)

• 2026-08-06 (confirmed): Q1 FY2027 results, 6:00am ET, conference call 8:00am ET. The binary — first clean-comp quarter (CSL Plasma drag fully annualized) and the first hard read on whether Interventional Technologies has stabilized. This is the event Citi's downside watch targets. Earnings blackout begins ~Aug 1 (within 3 trading days).
• No FDA/PDUFA or other dated binary in the window; single-stock earnings risk dominates.

Elapsed catalysts

• 2026-07-08 → early August: Citi's 90-day downside catalyst watch is live; expect further sell-side positioning notes into the print. (passed 20d ago)

What Would Change Our Mind

• A weekly close below $70 forfeits the reclaimed May–June breakout shelf and confirms the recovery leg has failed; a defended $70 keeps the base intact and the pivot thesis alive.
• To the upside, a clean weekly close above $80 on volume would reopen the path to the $83–90 consensus cluster and the $87.32 high, turning a stalled recovery back into an accelerating one worth pressing.
• Fundamentally, the August 6 print is the arbiter: IVT vascular-closure and EP declines lapping as guided, plus Plasma organic strength holding, validates the pivot; renewed IVT erosion without a plasma or Hospital offset breaks it regardless of the tape.

Correlation Notes

• Moves on its own fundamentals and the plasma end-market; low beta to the AI/semis complex, closer to a portfolio-ballast profile than a momentum vehicle.
• Plasma collection tracks IVIG/immunoglobulin demand — read-through from CSL, Grifols and Takeda plasma commentary. CSL is both a demand signal and a lost-customer overhang via the non-renewed U.S. disposables pact.
• The Hospital segment (TEG hemostasis, vascular closure, EP) tracks elective-procedure volumes and hospital capex cycles rather than macro-rate sensitivity.
• Over the next month, idiosyncratic earnings risk into August 6 outweighs sector or index correlation.

Sources

• Q1 FY2027 date: BioSpace, StockTitan
• Citi catalyst watch: TipRanks, GuruFocus
• Price/quote: StockAnalysis
• Q4 FY2026 8-K: SEC